UCB SA (OTCMKTS:UCBJY) Short Interest Up 2,250.0% in December

UCB SA (OTCMKTS:UCBJY) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 4,700 shares, an increase of 2,250.0% from the December 15th total of 200 shares. Based on an average trading volume of 13,700 shares, the short-interest ratio is presently 0.3 days.

UCB Price Performance

OTCMKTS:UCBJY traded down $0.26 during midday trading on Wednesday, reaching $97.63. The company had a trading volume of 9,673 shares, compared to its average volume of 10,209. UCB has a 12-month low of $44.26 and a 12-month high of $100.66. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock’s fifty day simple moving average is $96.69 and its 200-day simple moving average is $90.75.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.